Tag Archives: personalized medicine

Rayno Biopharmaceutical Portfolio Nov. 1, 2013 YTD Performance

Rayno 2013 Picks Outperform Biotechnology Indices and Funds  Biopharmaceutical stocks hit all time highs in 2013 with major ETFs up as follows YTD: FBT ($65) up 41%, IBB ($206) up 50%, and XBI ((%120) up 36%. The Five Star Fidelity Select Biotechnology Fund (FBIOX $171) is up 54.5% YTD. You can see our top picks […]

Comments Off Continue Reading →

Biotech Stocks Have A Bit of a MO-Off Day: AEGR, PCYC, MDVN, REGN

Biotech Stocks Take A Breather: NASDAQ off 0.3% at 3597 A little profit taking has set in after it seemed that the market would roar all summer. From the action in mid-cap biopharma stocks it looks like hedge funds are taking some off among high flyers.NASDAQ has been up for 14 straight days or 18% […]

Comments Off Continue Reading →

ASCO Day 2 Briefs and Daily Movers: ARRY,GILD,IBB,IMGN,SGEN

Apparently ASCO Is “Sell On the News” Trigger Another lackluster trading day with profit taking; the IBB  is down 2.3% and trading near its May bottom with a pronounced topping pattern.Moreover many funds and indices now own biotech stocks so without the general market rallying ((NASDAQ off 22 pts at 2:30 p EDT), the sector will […]

Comments Off Continue Reading →

Reiterate Caution on Biopharmaceutical Stocks With Major 3% Sector Sell-Off

Raise More Cash- No Change in Rayno Biopharma Portfolio Last month we raised the yellow flag on the biotech sector because of a choppy tape, new highs with weakness in MO (Momentum) plays and the anticipation of ASCO news that could trigger a “sell on the news” trend. Moreover CNBC pundits have been pushing biotech […]

Comments Off Continue Reading →

Rayno Biopharmaceutical Portfolio Performance- After Sell-Off 2/26/13

 Caution-Follow Technicals-Potential for Macro Risk Off The Life Science sector is about 2% off highs of February 1 and has formed a double top from October 5 highs. In recent posts we urged caution as some MO stocks had blow-off tops (ALXN,MDVN, REGN) and the IBB and XBI were unable to reach new highs with […]

Comments Off Continue Reading →

Personalized Healthcare Gets a Boost from Nestle/Prometheus Deal

The Life Science market consolidation trend continued  today as Nestle SA acquires privately held Prometheus Laboratories, Inc. of San Diego,CA for about $567M according to a Bloomberg story although the price was not disclosed. Other stories put the price closer to $1B.Prometheus was forecasted to have revenues of $250M next year (they might be much higher) […]

Comments Off Continue Reading →